This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech

St. Jude Medical (STJ) Stock Down Despite Positive Earnings Report

St. Jude Medical (STJ) Stock Down Despite Positive Earnings Report

  • Tickers in this article:
  • STJ

St. Jude Medical (STJ) tumbles in trading despite beating analysts EPS estimates by 1 cent

04/16/14 - 11:42 AM EDT

How Will This Earnings Report Affect Abbot Laboratories (ABT) Stock Today?

  • Tickers in this article:
  • ABT

Abbot Laboratories (ABT) earnings report beats EPS estimates but falls short on revenue

04/16/14 - 09:53 AM EDT

Will This Coverage Initiation Help Regeneron (REGN) Stock Today?

Will This Coverage Initiation Help Regeneron (REGN) Stock Today?

Regeneron Pharmaceuticals (REGN) had coverage initiated on its shares with a 'buy' rating by analysts at Canaccord Genuity

04/16/14 - 08:43 AM EDT

Article
How Will This Earnings Report Affect Abbot Laboratories (ABT) Stock Today?

How Will This Earnings Report Affect Abbot Laboratories (ABT) Stock Today?

  • Tickers in this article:
  • ABT

Abbot Laboratories (ABT) earnings report beats EPS estimates but falls short on revenue

04/16/14 - 09:53 AM EDT

Article
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.

04/16/14 - 08:00 AM EDT

Article
Bubble Bursting? Only for Biotech & Internet Stocks

Bubble Bursting? Only for Biotech & Internet Stocks

The recent sluggish performance of U.S. stocks is leading some market watchers to question whether we're witnessing the bursting of an equity bubble.

04/15/14 - 11:48 AM EDT

Article
Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Investors say Johnson & Johnson's earnings beat will take the Dow and the biotech sector higher today.

04/15/14 - 11:04 AM EDT

Article
Capitulation? Or a Bounce to Sell Into Now?

Capitulation? Or a Bounce to Sell Into Now?

Prepare yourself for more downside even if we do bounce this week.

04/14/14 - 11:37 AM EDT

Video
Stocks Open Higher on Citi Surprise, Surging Retail Sales Stocks Open Higher on Citi Surprise, Surging Retail Sales
  • Tickers in this article:
  • C
  • GSK

Stocks opened higher open on Monday, buoyed by better-than-expected earnings from Citigroup, while retail sales jumped 1.1% in March, surpassing economists' expectations.

04/14/14 - 09:53 AM EDT

Article
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.

04/11/14 - 03:07 PM EDT

Article
Oh Biotech, You Are a Cruel Bitch

Oh Biotech, You Are a Cruel Bitch

Wednesday's mini rally was a head fake, leading to more selling Thursday.

04/10/14 - 01:09 PM EDT

Video
Markets Jump on Fed Minutes, Loose Policy Stance Reiterated Markets Jump on Fed Minutes, Loose Policy Stance Reiterated
  • Tickers in this article:
  • DJI
  • IXIC

Biotech and social media stocks continued their rebound after selling off earlier this year, while earnings season was off to a promising start after strong results from bellwether stock Alcoa.

04/09/14 - 04:22 PM EDT

Article
When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.

When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.

  • Tickers in this article:
  • NWBO

An explanation of Northwest Bio's "up to" $32 million financing deal.

04/10/14 - 10:24 AM EDT

Article
Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.

04/09/14 - 10:06 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs